ACADIA Pharmaceuticals (ACAD) Stock Forecast & Price Target

$16.37 +0.19 (+1.17%)

(As of 11/22/2024 ET)

ACADIA Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 17 Analyst Ratings

Sell
0

Hold
6

Buy
11

Based on 17 Wall Street analysts who have issued ratings for ACADIA Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 17 analysts, 6 have given a hold rating, and 11 have given a buy rating for ACAD.

Consensus Price Target

$25.56
56.15% Upside

According to the 17 analysts' twelve-month price targets for ACADIA Pharmaceuticals, the average price target is $25.56. The highest price target for ACAD is $42.00, while the lowest price target for ACAD is $19.00. The average price target represents a forecasted upside of 56.15% from the current price of $16.37.

Get the Latest News and Ratings for ACAD and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for ACADIA Pharmaceuticals and its competitors.

ACAD Analyst Ratings Over Time

Type	Current Forecast 11/25/23 to 11/24/24	1 Month Ago 10/26/23 to 10/25/24	3 Months Ago 8/27/23 to 8/26/24	1 Year Ago 11/25/22 to 11/25/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	11 Buy rating(s)	11 Buy rating(s)	11 Buy rating(s)	9 Buy rating(s)
Hold	6 Hold rating(s)	6 Hold rating(s)	5 Hold rating(s)	3 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$25.56	$25.56	$25.56	$35.67
Forecasted Upside	56.15% Upside	78.26% Upside	58.87% Upside	60.01% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

Breaking News: Tesla headed to $500… (Ad)

That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla.

So to claim your free digital copy today, simply follow this link and enter your email address.

ACAD Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ACAD Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

ACADIA Pharmaceuticals Stock vs. The Competition

Type	ACADIA Pharmaceuticals	Medical Companies	S&P 500
Consensus Rating Score	2.65	2.80	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	56.15% Upside	27,073.48% Upside	7.66% Upside
News Sentiment Rating	Neutral News See Recent ACAD News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/7/2024	HC Wainwright 2 of 5 stars		Reiterated Rating	Buy ➝ Buy	$27.00 ➝ $27.00	+70.99%
11/7/2024	Needham & Company LLC 3 of 5 stars		Reiterated Rating	Buy ➝ Buy	$28.00 ➝ $28.00	+77.33%
10/10/2024	Raymond James 4 of 5 stars	D. Brill Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
8/8/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$30.00 ➝ $23.00	+48.67%
8/8/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$25.00 ➝ $23.00	+49.45%
8/7/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$37.00 ➝ $28.00	+82.17%
Get the Latest News and Ratings for ACAD and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for ACADIA Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.
8/7/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$29.00 ➝ $26.00	+67.31%
8/7/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Overweight ➝ Equal Weight	$28.00 ➝ $20.00	+6.10%
6/27/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	E. Seigerman Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$31.00	+100.00%
5/10/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$26.00 ➝ $22.00	+44.64%
5/9/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Hold ➝ Hold	$26.00 ➝ $21.00	+30.84%
5/9/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$31.00 ➝ $28.00	+63.46%
5/9/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$25.00 ➝ $21.00	+22.59%
5/6/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Market Perform ➝ Market Perform	$19.00 ➝ $19.00	+11.44%
3/25/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$29.00 ➝ $25.00	+40.53%
2/7/2024	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Market Outperform ➝ Market Outperform	$42.00	+66.67%
12/12/2023	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy ➝ Buy	$25.00	+18.54%
8/3/2023	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$39.00 ➝ $38.00	+36.01%
4/28/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$93.00 ➝ $95.00	+363.41%
3/14/2023	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$22.00 ➝ $25.00	+28.80%
3/14/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$10.00 ➝ $15.00	-22.72%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 11:41 PM ET.

ACAD Forecast - Frequently Asked Questions

: According to the research reports of 17 Wall Street equities research analysts, the average twelve-month stock price forecast for ACADIA Pharmaceuticals is $25.56, with a high forecast of $42.00 and a low forecast of $19.00.
: 17 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ACADIA Pharmaceuticals in the last year. There are currently 6 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ACAD shares.
: According to analysts, ACADIA Pharmaceuticals's stock has a predicted upside of 56.15% based on their 12-month stock forecasts.
: ACADIA Pharmaceuticals has been rated by research analysts at HC Wainwright, Needham & Company LLC, and Raymond James in the past 90 days.
: Analysts like ACADIA Pharmaceuticals less than other "medical" companies. The consensus rating score for ACADIA Pharmaceuticals is 2.65 while the average consensus rating score for "medical" companies is 2.80. Learn more on how ACAD compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Trump won. Buy this coin now. (Ad)

Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.

This could be his favorite coin.

This page (NASDAQ:ACAD) was last updated on 11/24/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ACADIA Pharmaceuticals (ACAD) Stock Forecast & Price Target